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Background: Vitamin D is involved in calcium and bone ho-
meostasis and has immunomodulatory effects. Vitamin D
deﬁciency prior to HSCT has been associated with higher risk
of chronicGVHD in adultswithmalignancies. The signiﬁcance
of vitamin D deﬁciency on transplant outcomes in pediatric
and young adult HSCT patients is not well understood.
Methods: Serum samples from consecutive HSCT patients
prospectively enrolled onto HSCT repository at our institu-
tion were tested for 25-hydroxy (25-OH) vitamin D levels
prior to starting HCST (baseline) and at 100 days after
transplantation. A 25-OH vitamin D level of <30 ng/ml was
deﬁned as vitamin D deﬁciency and <20 ng/ml as severe
vitamin D deﬁciency. Continuous and categorical variables
were compared using Wilcoxon Rank Sum test and Fisher’s
exact test, respectively. Survival and cumulative incidence
curves were computed using Kaplan Meier and were tested
using Log Rank and Gray’s test, respectively.
Results: Pre-transplant (baseline) serum samples were
tested for 25-OH Vitamin D level in 135 consecutive HSCT
patients; 21% of whom were already receiving vitamin D
supplementation. Ninety-four of 135 (70%) patients had
Vitamin D level <30ng/mL despite supplemental therapy in
16% of subjects. Post-transplant serum samples were avail-
able in 129 patients who survived to day 100 post-HSCT.
Vitamin D deﬁciency persisted in 66 of 87 patients (76%) who
were already deﬁcient at baseline and survived to 100 days
post-HSCT. Twenty-four (57%) patients with normal vitamin
D levels prior to transplant developed Vitamin D deﬁciency
by 100 days after transplantation. Overall 70% of all patients
surviving 100 days after transplantation had low vitamin D
levels, with the third of them having severe Vitamin D
deﬁciency (<20ng/ml). Low vitamin D levels at baseline prior
to HSCT were not associated with development of either
acute or chronic GVHD (p¼0.8), contrary to reports in adults.
However, severe vitamin D deﬁciency (<20 ng/ml) at 100
days post-HSCT was associated with decreased overall sur-
vival after transplantation (p¼0.044, Figure).
Conclusions: Pediatric and young adult patients undergoing
HSCT are at high risk for vitamin D deﬁciency, both before
and after HSCT, more so than general population. This places
them at high risk for skeletal and nutritional complications.
Severe vitamin D deﬁciency at 100 days after-transplantation
is associated with worse overall survival and likely repre-
sents ongoing chronic illness. Pre-transplant screening and
aggressive vitamin D therapy is indicated in these patients to
improve long-term outcomes after HSCT.108
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Background:Myelo-ablative chemotherapywith autologous
stem cell rescue, local radiotherapy and chimeric antibody
are routinely given post-induction in the management of
high-risk neuroblastoma (NBL). The Children’s Oncology
Group (COG) recently reported the prognostic impact of a
semi-quantitative MIBG-based scoring method, termed Cu-
rie scoring (CS) in high-risk disease. In particular, post-in-
duction (pre-transplant) CS >2 were associated with poor
event-free (EFS) and overall survival (OS). We now validate
the impact of Curie scoring in an independent data set, the
SIOPEN-HR-NBL1 (SIOP-NB) study.
Methods: MIBG scans from patients with MIBG avid, INSS
stage 4 neuroblastoma enrolled on SIOP-NB were evalu-
ated post-induction (n¼330), prior to transplant. Scans
were evaluated in 10 different anatomic regions by 2 re-
viewers, including 9 skeletal segments and 1 soft issue
region. Each region was scored 0-3 based upon disease
extent, and a cumulative consensus score generated.
Optimal cut-points from post-induction scans were deter-
mined using the Youden index, with EFS and OS deter-
mined. Post-induction CS from patients enrolled on COG
A3973 (n¼237) were used for comparison. Patients
received busulfan-melphalan (BuMel) in SIOP-NB, and
carboplatin-etoposide-melpahlan (CEM) in COG A3973, as
transplant conditioning.
Results: The optimal CS cut-point post-induction (pre-
transplant) was 2 in both SIOP-NB and COG A3973, with a
post-induction CS >2 associated with inferior outcomes in
each study. In SIOP-NB, 5-year EFS were 39.24.7% vs
16.44.2% for patients with post-induction CS 2 vs >2
(p<0.001). In comparison, 5-year EFS were 42%5.8% vs
10.5%10.0% (p<0.001) for patients with post-induction CS
2 vs >2 in COG A3973. A post-induction CS >2 carried
prognostic signiﬁcance for both MYCN ampliﬁed and MYCN
non-ampliﬁed tumors, in both SIOP-NB and COG A3973. In
particular, post-induction CS >2 were associated with
extremely poor outcomes for patients with MYCN ampliﬁed
disease, with a 5-year EFS 13.8%12% in SIOP-NB. The post-
induction CS maintained independent statistical signiﬁcance
in Cox models when compared to standard predictive cova-
riates age and MYCN in both trials.
Conclusion: The prognostic signiﬁcance of post-induction
CS has now been validated in an independent cohort of
patients, with a post-induction CS >2 associated with
inferior outcome in two large cooperative group trials,
SIOPEN-HR-NBL1 and COG A3973. MIBG scoring should be
incorporated into pre-transplant evaluations in high-risk
NBL, and patients with CS >2 considered for alternative
regimen.
